Torres-López J

Idioma: Español
Referencias bibliográficas: 11
Paginas: 1-2
Archivo PDF: 323.24 Kb.

RESUMEN

Hasta el día de hoy, no se cuenta con un tratamiento para los pacientes infectados con SARS-CoV-2. Se están llevando a cabo estudios en varios países y algunos han arrojado resultados prometedores; sin embargo, aún no se ha logrado identificar un tratamiento efectivo para combatir el COVID-19, una de las amenazas más serias que ha sufrido la humanidad en los últimos 100 años.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020. DOI: 10.1056/NEJMoa2001282

2. Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YSE et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. PNAS. 2004;101(27): 10012-7. DOI: 10.1073/pnas.0403596 101

3. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L et al. Treatment with Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015;212(12): 1904-13. DOI: 10.1093/infdis/ jiv392

4. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mahile M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. DOI: 10.1016/j.ijantimicag.2020.105949

5. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends. 2020;14(1):72- 73. DOI: 10.5582/bst.2020.01047

6. Boulware D. Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP). Minneapolis, MN: University of Minnesota; 2020. 2 Disponible en: https://clinicaltrials.gov/ct2/show/ NCT04308668?cond=Coronavirus&cntry=US&state =US%3AMN&draw=2&rank=1

7. Dalgard O. Norwegian Coronavirus Disease 2019 Study (NO COVID-19). Akhershus, Norway: Akerhus University Hospital; 2019. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04316377?ter m=chloroquine+and+covid-19&draw=2&rank=3

8. Schilling W. Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV). Oxford, UK: University of Oxford; 2020. Disponible en: https:// clinicaltrials.gov/ct2/show/NCT04303507?term=chl oroquine+and+covid-19&draw=2&rank=1

9. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research.2020;30:269-271. Disponible en: https://www.nature.com/articles/ s41422-020-0282-0

10. Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT, Sandoval-Espinosa C et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A. 2016; 113(50):14408-14413. Disponible en: https://www. ncbi.nlm.nih.gov/pubmed/27911847

11. Madrid PB, Panchal RG, Warren TK, Shurtleft AC, Endsley AN, Green CE et al. Evaluation of Ebola Virus Inhibitors for Drug Repurposing. ACS Infect Dis. 2015; 1(7):317-26. DOI: 10.1021/acsinfecdis.5b00030